Abstract:BACKGROUND & OBJECTIVE:Vinorelbine (NVB), paclitaxel (TAX), and gemcitabine (GEM) are first-line chemotherapeutic drugs in the treatment for non-small cell lung cancer (NSCLC) currently. There are many domestically retrospective studies to compare efficacies and adverse reactions among these three regimens, all of which has composed of cisplatin (DDP). This randomized study was to investigate the efficacies and toxicities of these three regimens in NSCLC treatment, in order to choose a feasible regimen for NSCLC patients.METHODS:A total of 276 NSCLC patients were randomly assigned to a regimen of NP (NVB plus DDP ), or TP (TAX plus DDP), or GP (GEM plus DDP). Efficacies and toxicities were analyzed and compared after two cycles.RESULTS:The response rates were 42.3% (41/97) in NP arm, 43.0% (40/93) in TP arm, and 43.4% (36/83) in GP arm, and complete remission rates were 1.0% (1/97), 2.2% (1/93) and (0/83) respectively, without significant difference. The median survival time, disease-free survival time and 1-year survival rate were 8.5 months, 4.1 months and 31.9%; 8.8 months, 3.8 months and 33.3%, and 9.2 months, 3.9 months, 31.3%, respectively in NP, TP and GP arms without significant difference. The major adverse reactions were stage 3 to 4 myelo-suppression, nausea/vomiting, fatigue and phlebitis. There were highest incidences of leucopenia (42.2%), neutropenia (36.2%) and lowest incidence of thrombocytopenia (53.0%) in GP arm compared to NP arm (77.8%, 67.7%, 12.1%) or TP arm (71.0%, 57.0%, 13.0%) statistically (P<0.01 for all). The rates of nausea/vomiting in GP arm (16.8%) and TP arm (25.8%) were significantly lower than in NP arm (41.4%)(P<0.05); and the rate of fatigue in GP arm (38.5%) or phlebitis in NP arm was most frequent among the three arms (P=0.000, 0.008 respectively).CONCLUSIONS:There is no significant difference in short-term efficacy of chemotherapy regimen NP, TP and GP. TP and GP regimens, both of which possesses its own advantage, are more tolerable than NP regimen which has the most side effects.

Observation on Efficacy of NP Regimen Combined with Qingrejiedu Decoction in Treatment of Non-Small Cell Lung Cancer: a Report of 72 Cases

A Clinical Study on Efficacy and Toxicity of NP in Contrast to the MNP Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer

First-line regimen of Vinorelbine and Cisplatin(NP) combined with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-cell lung cancer

Post-operative treatment with cisplatin and vinorelbine in Chinese patients with non-small cell lung cancer: a clinical prospective analysis of 451 patients.

First-line chemotherapy of vinorelbine/cisplatin (NP) combined with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-cell lung cancer (NSCLC): P2-327

Clinical Observation of NVB and Carboplatin in the Management of Advanced Non-Small Cell Lung Cancer

Vinorelbine plus cisplatin in the treatment of 48 cases with advanced non-small-cell lung cancer

Comparison of Cisplatin-Mitomycin-vinorelbine Versus Cisplatin-Mitomycin-vindesine Regimen for Treatment of Advanced Non-Small Cell Lung Cancer: a Report of 83 Patients

Comparison of Different Regimen in Treatment of Patients with Advanced Non-Small Cell Lung Cancer

A Randomized Comparative Trial of NVB Alone Versus NVB Plus DDP for Treatment of Elderly Patients with Non-Small Cell Lung Cancer

Chemotherapy Based on Regimes of Gemcitabine Plus Cisplatin or Vinorelbine Plus Cisplatin in Patients with Advanced NSCLC

Treatment of Advanced Non-small-Cell Lung Cancer with Qi-Nourishing Essence-Replenishing Chinese Herbal Medicine Combined with Chemotherapy

Comparison of Short-term Efficacy between the NP and GP Regimens in the Treatment of Advanced Non-small-cell Lung Canaer

Clinical Observation of Chemotherapy with NP and GP Regimens on Advanced Non-Small Cell Lung Cancer Patients

Observation of Short-Term Therapeutic and Adverse Effect of Lentinan and Venorelbine and Oxaliplatin Recombination on Patients with Advanced Non-Small Cell Lung Cancer

Compare and Evaluate Two Combination Regimens of Vinorelbine Plus Gemcitabine and Cisplatin Pins Vinorelbine for Treatment of Patients with Advanced Non-Small-cell Lung Cancer

A Randomized Trial Comparing Oxaliplatin Plus Vinorelbine Versus Cisplatin Plus Vinorelbine for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

[A Randomized Comparative Trial of Three Combined Regimens Containing Cisplatin for Treatment of Advanced Non-Small Cell Lung Cancer].

A Randomized Clinical Trial of NVB Plus DDP with Rh-endostatin in the Treatment of Advanced Retreated Non-Small-cell Lung Cancer Patients

Xiaoaiping Injection Combined with Cisplatin and Gemcitabine for Non-Small Cell Lung Cancer: A Clinical ObservationΔ

The application of different chemotherapy regimens in non-small cell lung cancer